Common use of Källförteckning Clause in Contracts

Källförteckning. ■ Pressmeddelande 2019-12-04: xxxxx://xx.xxxxxx.xxx/Xxxx/0000/0000000/0000000.xxx ■ Årsredovisning 2018: xxxxx://xx.xxxxxx.xxx/Xxxx/0000/0000000/0000000.xxx ■ CANTOS-studien: New England Journal of Medicine 2017; 377:1119-1131 ■ Xxxxxxxxxxxxxx.xxx ■ Advancing Health Through Innovation 2018 New Drug Therapy Approvals, FDA ■ Journal of Clinical Investigation 2015;125(8):3063–3076 ■ Journal of Xxxxx'x and Colitis, Volume 12, Issue supple- ment_1, 1 February 2018, sid S070 ■ World Journal of Cardiology 2017;9(5):407–415. ■ GlobalData’s report: PharmaPoint: Heart Failure – Global Drug Forecast and Market Analysis to 2026. ■ Epidemiology of Myocardial Infarction Xxxxx et al., DOI: 10.5772/intechopen.74768, Nov. 2018 ■ Circ Heart Fail. 2016 Jan; 9(1): e002460. doi: 10.1161/CIRCHE- ARTFAILURE.115.002460 ■ First-in-class oral small molecule inhibitor of the tyrosine ki- nase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells. Hojjat-Farsangi M, Xx- xxxxxxxxxx XX, Xxxx AS, Xxxxxx J, Xxxxxxxxx F, Xxxxxxxxx P, Xxxxxx LS, Xxxxxxx P, Xxxxxxx L, Xxxxxxx J, Xxxxxxx S, Ols- son E, Xxxxxxx C, Xxxxxxxx C, Xxxxxxx J, Xxxxx M, Xxxx T, Xxxxx- xxxx A, Xxxxxxxxx H, Xxxxxxxx X. Leukemia. 2018 Oct;32(10):2291-2295. doi: 10.1038/s41375-018-0113-1. Epub 2018 Mar 27. ■ Targeting PFKFB3 radiosensitizes cancer cells and suppres- ses homologous recombination. Gustafsson NMS, Färne- gårdh K, Xxxxxxx N, Xxxxx XX, Xxxxx P, Xxxxx E, Xxxxxxx M, Xxxxxxxx K, Xxxxx J, Xxxxxxx R, Xxxxxxxxxx J, Xxxxxxxx C, Xxx- xxxx J, Xxxxxxx J, Xxxxxxxxx M, Xxxxxxx N, Xxxxxxxx P, Xxx B, Xxxxx M, Xxxx T, Xxxxxxxx X. Nat Commun. 2018 Sep 24;9(1):3872. doi: 10.1038/s41467-018-06287-x. ■ A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) in- duced significant apoptosis of pancreatic cells which was en- hanced by erlotinib and ibrutinib. Daneshmanesh AH, Hojjat-Farsangi M, Xxxxxxx A, Xxxxxxxx A, Xxxxxxx L, Xxxxxxx J, Xxxxxxx J, Xxxxxxx S, Xxxxxx E, Xxxx T, Xxxxxxxxx A, Xxxxxxxxx X. PLoS One. 2018 Jun 1;13(6):e0198038. doi: 10.1371/journal.pone.0198038. eCollection 2018. EU-TILLVÄXTPROSPEKT FÖR KANCERA AB (PUBL), MARS 2020 11

Källförteckning. ■ Pressmeddelande 2019Artikel: Xxxxxxx XX, Xxxxx LA, Xxxxxxx H, Xxxxxx C, Xxxxxx L, Xxxxxxx-12Xxxxx, X. Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-04: xxxxx://xx.xxxxxx.xxx/Xxxx/0000/0000000/0000000.xxx ■ Årsredovisning analyses- Part I. Inflammatory Bowel Diseases. Vol 24, nr. 4, 2018: xxxxx://xx.xxxxxx.xxx/Xxxx/0000/0000000/0000000.xxx ■ CANTOS742-studien: New England Journal of Medicine 2017; 377:1119-1131 ■ Xxxxxxxxxxxxxx.xxx ■ Advancing Health Through Innovation 2018 New Drug Therapy Approvals, FDA ■ Journal of Clinical Investigation 2015;125(8):3063–3076 ■ Journal of Xxxxx'x and Colitis, Volume 12, Issue supple- ment_1, 1 February 2018, sid S070 ■ World Journal of Cardiology 2017;9(5):407–415. ■ GlobalData’s report: PharmaPoint: Heart Failure – Global Drug Forecast and Market Analysis to 2026. ■ Epidemiology of Myocardial Infarction Xxxxx et al., DOI: 10.5772/intechopen.74768, Nov. 2018 ■ Circ Heart Fail. 2016 Jan; 9(1): e002460751. doi: 10.116110.1093/CIRCHE- ARTFAILURE.115.002460 ■ First-in-class oral small molecule inhibitor of the tyrosine ki- nase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells. Hojjat-Farsangi ibd/izy015 • Artikel: Xxxxxxxxx, T, Xxxxxxxx, B, Xx Xxxxx, C, Xxxx Xxx, S, Xxxxxxxx, M, Xx- xxxxxxxxxx Xxxx, B, Xxxxxxxxx, CN, Xxxxxx, S, Peyrin-Biroulet, L, Xxxx, X. Ulcerative colitis. Nature reviews disease primers. Vol 6, nr. 74, 2020. xxxxx://xxx.xxx/00.0000/x00000-000-0000-x • Artikel: Xxxxx RD, Xx AP, Xx XX, Xxxx ASXxx J, Xxxxxx PM, Xxxx X. Systematic review: the costs of ulcerative colitis in Western countries. Alimentary Pharmacology & Therapeutics. Vol 31, nr. 7, 2010: 693-707. doi: 10.1111/j.1365-2036.2010.04234.x • Artikel: Xxxxxxxxxx, J, Xxxxxxxxx FXxxxxxxx, Xxxxxxxxx P, Xxxxx, D, Xxxxx, X. Indirect costs associated with ulcerative colitis: a systematic literature review of real-world data. BMC Gastroenterology. Vol 19, nr. 179, 2019. doi: 10.1186/ s12876-019-1095-9. • Rapport: The Crohn’s & Colitis Foundation of America (CCFA). The facts about Inflammatory Bowel Diseases. 2014. • Artikel: Xxxxxx LSS, Xxxxx M, Xxxxxxxxxx A, Xxxxx I, Xxxxxxx J, Xxxx A, Xxxxxxx P, Xxxxxxx Xxxxx F, Peyrin-Biroulet L, Xxxxxxx JXxxxxxxxx S, Xxxxxxx S, Ols- son E, Xxxxxxx CD, Xxxxxxxx C, Xxxxxxx J, Xxxxx M, Xxxx T, Xxxxx- xxxx A, Xxxxxxxxx H, Xxxxxxxx X. Leukemia. 2018 Oct;32(10):2291-2295. doi: 10.1038/s41375-018-0113-1. Epub 2018 Mar 27. ■ Targeting PFKFB3 radiosensitizes cancer cells and suppres- ses homologous recombination. Gustafsson NMS, Färne- gårdh K, Xxxxxxx N, Xxxxx XX, Xxxxx P, Xxxxx E, Xxxxxxx M, Xxxxxxxx K, Xxxxx J, Xxxxxxx RS, Xxxxxxxxxx J, Xxxxxxxx S; Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus, Dig Dis. 2019;37(4):266-283. • Artikel: Altwegg R, Xxxxxxx, X. TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease. Mediators of Inflammation. Vol 2014, 2014: Article ID 172821. xxxxx://xxx.xxx/00.0000/0000/000000 • Artikel: Xxxxxxxx WJ, Xx X, Xxxxx BE, X’Xxxxx GR, Xxxxxxxx S, Xxxxxxxxx S, Xxxxxx S, Xxxxxx BG, Xxxxxxxx W, Xxxxxxxxxxxx W, Xxxxxxxx G, Xxxxxxx N, Xx X, Xxxxxxxxx D, Xxxxxxxxx A, Xxxxx H, Xxxxxx P, Xxxxx J; XXXXXX Induction 1, XXXXXX Xxxxxxxxx 2, and XXXXXX Xxxxxxx Investigators. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. The New England Journal of Medicine. Vol 18, nr. 376, 2017. xxxxx://xxx.xxx/00.0000/x00000-000-0000-0 • Artikel: Xxxxxxx, M, Xxx Xxx, E, Xxxxxxxx, XX. JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications. Journal of Crohn’s and Colitis. Vol 14, Issue Supplement 2, 2020: 755–760. xxxxx://xxx.xxx/00.0000/xxxx-xxx/xxxx000 • Artikel: Xxx, M, Xxxxxx, D, Xxxxxxxxx, J, Xxxxxxxxxx, C, Xxx- xxxx Xxxxxxxxx, X. Clinical development success rates for investigational drugs. Nature Biotechnology. Vol 32, 2014: 40–51. xxxxx://xxx.xxx/00.0000/xxx.0000 • Kapitel: Xxxxxx, X. The Pharmaceutical Industry and the Future of Drug Development. I Pharmaceuticals in the Environment. 2015: 1-33. doi: 10.1039/9781782622345-00001. • Artikel: Atreya, R, Xxxxxx-Xxxxxxxx, L, Xxxxxxxx, A, Xxxxxxxx, M, Xxxxxxx, I, Xxxxxxxxxxx, D, Xxxxxxxx, P, Xxxxxxxxxx, A, Xxxxxxxxx, X, Xxxxxxxx, K, Xxxxxxx, T, Xxxxxxxx, J, Xxxxxxx, MF, Xxxxxxxx, XX, Xxxxxxxx, X. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. The Lancet Gastroenterology & Hepatology. Vol 5, nr. 12, 2020: 1063-1075. xxxxx://xxx.xxx/00.0000/X0000-0000(00)00000-0. • Artikel: Xxxxxx, A, Xxxxx, S. Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases. Expert Review of Clinical Immunology. Vol 15, nr. 9, 2019: 969-979. xxxxx://xxx.xxx/00.0000/0000000X.0000.0000000 • Artikel: Xxxxxxx, H, Xxxxxxxxxxxx, J, Xxxxxxxxx, U, Xxxxx, M, Xxxxxxxx, P, Xxxxxxxxx, S, Xxxx, S, Xxxxxx, I, Xxxx, T, Xxxxxxx, S, Xxxxxxxxxxxx, M, Xxxxxxxxx, J, Xxxxxxxx, A, Xxxxxxx, T, Xxxxxx, C, Xxxxxxx, T, Xxxxxxxxx Xxxxxxxxx, C, Xxxxxxx, A, Xxxxxxx, MF, Xxxxxx, X. The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis. Journal of Crohn’s and Colitis. Vol 14, nr. 4, 2020: 508–524. xxxxx://xxx.xxx/00.0000/xxxx-xxx/xxx000 • Artikel: Xxxxxxxxx P, Xxxxxxxx WJ, Xxxxxx BG, Xxxxxxxx W, Xxxxx A, Xxxxxxx X, Xxxxxxx S, Xxxxxxxxxxxx D, Xxxxxxx SB, Xxxxxxxxxxxx GR, de Xxxxxxxx WJ, Present D, Xxxxx BE, Xxxxxxxx JF. Infliximab for induction and maintenance therapy for ulcerative colitis. The New England Journal of Medicine. Vol 23, nr. 353, 2005: 2462-76. doi: 10.1056/ NEJMoa050516 • Artikel: Xxxxxxxx WJ, xxx Xxxxxx G, Xxxxxxxx W, Xxxxxxxx JF, D’Haens G, Xxxx DC, Xxxx M, Xxxxx MB, Xxxxx A, Xxxxxxx RB. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. Vol 2, nr. 142, 2011: 257-65. doi: 10.1053/j.gastro.2011.10.032 • Artikel: Xxxxxxxx WJ, Xxxxxx BG, Xxxxxx C, Xxxxx H, Xxxxxxx R, Xxxxxxx J, Xxxxxxxxx MXxxxxxxx OJ, Xxxxxxx NXxxxx C, Xxxxxxxx P, Xxx B, Xxxxx M, Xxxx TJF, Xxxxxxxx X. Nat Commun. 2018 Sep 24;9(1):3872. doi: 10.1038/s41467-018-06287-x. ■ A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) in- duced significant apoptosis of pancreatic cells which was en- hanced by erlotinib and ibrutinib. Daneshmanesh AHW, Hojjat-Farsangi M, Xxxxxxx A, Xxxxxxxx A, Xxxxxxx LXxxxxx PR, Xxxxxxx J, Xxxxxxx J, Xxxxxxx S, Xxxxxx EXxxxxxxx G, Xxxx T, Xxxxxxxxx AP; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. Vol 1, Xxxxxxxxx X. PLoS Onenr. 2018 Jun 1;13(6):e0198038146, 2014: 85-95. doi: 10.137110.1053/journal.pone.0198038j.gastro.2013.05.048 • Artikel: Xxxxxx BG, Xxxxxxxxx P, Xxxxx BE, Xxxxxxx S, Xxxxxxxx JF, Xxxxxxxx WJ, Xxx Xxxxxx G, Xxxxx J, Xxx HJ, Xxxxxx S, Xxx I, Xxxxx C, Xxxxxx S, Xxxxx T, Xx J, Xxxxxx A; GEMINI 1 Study Group. eCollection 2018Vedolizumab as induction and maintenance therapy for ulcerative colitis. EUThe New England Journal of Medicine. Vol 8, nr. 369, 2013: 699-TILLVÄXTPROSPEKT FÖR KANCERA AB (PUBL)710. doi: 10.1056/NEJMoa1215734 • Artikel: Xxxxx BE, MARS 2020 Xxxxxxxx WJ, Xxxxxxxxxx R, X’Xxxxx CD, Xxxxx H, Xxxxxxx X, Xxxxxxxx OJ, Xx X, Xxxxxx-Xxxxxxxx L, Xxx Xxxxxx G, Xxxxxx S, Xxxxxx S, Xxxxx MT, Xxxxxxxxx T, Xxxxxxx P, Xxxxxx C; UNIFI Study Group. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. The New England Journal of Medicine. Vol 13, nr. 381, 2019: 1201-1214. doi: 10.1056/NEJMoa1900750 • Artikel: Xxxxxx R, Xxxxx S, Xxxxxxxxxxx F, Xxxxxxx V, Xxxxxx X, Xxxxxxxx Å, Xxxxxxx T, Xxxxxxxx J, Xxxxx X, Xxxxxxx R, Xxxxxx X, Xxxxxxx R, Xxxxxxxxx G, Xxxxxxxx R, Xxxxxxx U, Xxxxxxx MF, Xxxxxx X. Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis. Journal of Crohn’s and Colitis. Vol 11, nr. 10, 2016: 1294-1302. doi: 10.1093/ ecco-jcc/jjw103 • Artikel: Xxxxxxxx FS, Xxxxx S, Xxxxxxx A, Xxxxxxx M. The biologics of ulcerative colitis. Expert Opinion on Biological Therapy. Vol 2, nr. 17, 2017: 175-184. doi: 10.1080/14712598.2017.1271871 Bakgrund och motiv 13

Källförteckning. ■ Pressmeddelande 2019-12-04: xxxxx://xx.xxxxxx.xxx/Xxxx/0000/0000000/0000000.xxx ■ Årsredovisning 2018: xxxxx://xx.xxxxxx.xxx/Xxxx/0000/0000000/0000000.xxx ■ CANTOS-studien: New England Journal of Medicine 2017; 377:1119-1131 ■ Xxxxxxxxxxxxxx.xxx ■ Advancing Health Through Innovation 2018 New Drug Therapy Approvals, FDA ■ Journal of Clinical Investigation 2015;125(8):3063–3076 ■ Journal of Xxxxx'x and Colitis, Volume 12, Issue supple- ment_1, 1 February 2018, sid S070 ■ World Journal of Cardiology 2017;9(5):407–415. ■ GlobalData’s report: PharmaPoint: Heart Failure – Global Drug Forecast and Market Analysis to 2026. ■ Epidemiology of Myocardial Infarction Xxxxx et al., DOI: 10.5772/intechopen.74768, Nov. 2018 ■ Circ Heart Fail. 2016 Jan; 9(1): e002460. doi: 10.1161/CIRCHE- ARTFAILURE.115.002460 ■ First-in-class oral small molecule inhibitor of the tyrosine ki- nase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells. Hojjat-Farsangi M, Xx- xxxxxxxxxx XX, Xxxx AS, Xxxxxx J, Xxxxxxxxx F, Xxxxxxxxx P, Xxxxxx LS, Xxxxxxx P, Xxxxxxx L, Xxxxxxx J, Xxxxxxx S, Ols- son E, Xxxxxxx C, Xxxxxxxx C, Xxxxxxx J, Xxxxx M, Xxxx T, Xxxxx- xxxx A, Xxxxxxxxx H, Xxxxxxxx X. Leukemia. 2018 Oct;32(10):2291-2295. doi: 10.1038/s41375-018-0113-1. Epub 2018 Mar 27. ■ Targeting PFKFB3 radiosensitizes cancer cells and suppres- ses homologous recombination. Gustafsson NMS, Färne- gårdh K, Xxxxxxx N, Xxxxx XX, Xxxxx P, Xxxxx E, Xxxxxxx M, Xxxxxxxx K, Xxxxx J, Xxxxxxx R, Xxxxxxxxxx J, Xxxxxxxx C, Xxx- xxxx J, Xxxxxxx J, Xxxxxxxxx M, Xxxxxxx N, Xxxxxxxx P, Xxx B, Xxxxx M, Xxxx T, Xxxxxxxx X. Nat Commun. 2018 Sep 24;9(1):3872. doi: 10.1038/s41467-018-06287-x. ■ A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) in- duced significant apoptosis of pancreatic cells which was en- hanced by erlotinib and ibrutinib. Daneshmanesh AH, Hojjat-Farsangi M, Xxxxxxx A, Xxxxxxxx A, Xxxxxxx L, Xxxxxxx J, Xxxxxxx J, Xxxxxxx S, Xxxxxx E, Xxxx T, Xxxxxxxxx A, Xxxxxxxxx X. PLoS One. 2018 Jun 1;13(6):e0198038. doi: 10.1371/journal.pone.0198038. eCollection 2018. Delivered by xxxxx://xxxxxx.xx EU-TILLVÄXTPROSPEKT FÖR KANCERA AB (PUBL), MARS 2020 11